Search results
MS Med Nearly Eliminates Disease Activity on MRI
Medscape· 1 day agoA second-generation anti-CD40L monoclonal antibody suppresses multiple sclerosis (MS) disease activity on MRI to an uncommonly high degree, new trial data suggested. Researchers found a near ...
Unprecedented PFS Results in ALK-Positive Lung Cancer Trial
MedPage Today· 6 days agoFive-year results from a phase III trial had experts gushing over lorlatinib's (Lorbrena)...
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Medscape· 5 days agoFive-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
Is Your Intellectual Property Safe With Indian CROs And CDMOs?
BioresearchOnline· 3 days agoPlease note: This is not a legal document, although I have included input from attorneys based in...
Tech Hubs Sprout Innovation
New Jersey Business Magazine· 3 days agoThe HELIX in New Brunswick, a $2-billion life science center that aims to be a leader of translational research in New Jersey and throughout the East...
Dividends Are a Benefit, But Only From Companies That Can Afford to Pay Them | Investing.com
Investing.com· 2 days agoFew financial topics have been the subject of more articles than dividend investing, and for good...
'Practice Changing' Trial for Inoperable Locally Advanced NSCLC
MedPage Today· 4 days agoEGFR testing now needed for all patients with stage III disease, experts say
Cell therapy reckoning: How to get cell therapies flying off-the-shelf
FierceBiotech· 6 days agoThis story is the final part of a four-part series about cell therapy created by the Fierce Biotech...
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma
MedPage Today· 4 days agoProgression-free survival (PFS) was significantly higher with belantamab mafodotin (belamaf;...
Improved Outcomes With Subcutaneous Amivantamab in NSCLC
Medscape· 4 days agoSubcutaneous amivantamab plus lazertinib may offer a survival benefit over intravenous administration, alongside dramatically reduced administration times, a new study suggests.
